# Convergence Check 30 - Wave69 Controller and Foundation-Model Gate

Timestamp: 2026-05-27 16:15 CEST

## Forcing Question

Do the 13 Wave68 parked genes converge on a less-blocked druggable controller,
and does a real-cell foundation-model perturbation screen support that
controller?

## Evidence Channels

1. **Hostile triage sidecar**

   Wave69-A found no direct therapeutic anchor among the 13 genes. It grouped
   them into blocked APC checkpoint/costimulation/cytokine genes, Fc/ROS
   myeloid genes, and weak cytoskeletal/locus tags.

2. **Independent validation sidecar**

   Wave69-B found no candidate ready to reopen. `RGS14` failed validation.
   `IL7R`, `CD274`, and `SP140` recur as expression/state markers but are
   blocked comparators. `FCGR2B` and `NCF1` move after anti-TNF in RA bulk
   synovium but not as cell-resolved controller evidence.

3. **Network/druggability/controller rank**

   Wave69 local controller ranking used OmniPath, Enrichr, ChEMBL, EuropePMC,
   ClinicalTrials.gov, and prior V3 blockers.

   After adding broad-kinase/checkpoint/JAK/TNF/Fc blockers, only:

   - `PRKDC`: connected to `NCF1;RGS14`, ChEMBL target `CHEMBL3142`, 3,093
     activity rows, 1 mechanism row, EuropePMC crowding hits 676.
   - `BLK`: connected to `FCGR2A;FCGR2B`, ChEMBL target `CHEMBL2250`, 1,174
     activity rows, no mechanism row in the queried ChEMBL mechanism endpoint.

   remained as `PARK_DRUGGABLE_CONTROLLER_SCOUT_NEEDS_DIRECT_VALIDATION`.

4. **Foundation-model perturbation**

   Wave69-D ran a local Geneformer V2-104M token-deletion screen on real
   `GSE282122` post-treatment non-remission cells, scored by movement toward
   post-treatment remission centroids.

   `PRKDC` and `BLK` did not pass:

   - `PRKDC`: `NO_GO_MODEL_REMISSION_SCREEN`; insufficient token-supported
     non-remission cells and no support context.
   - `BLK`: `NO_GO_MODEL_REMISSION_SCREEN`; no detected token in selected
     GSE282122 myeloid/DC non-remission cells.

   Model support was restricted to blocked comparators:

   - `FCGR2A`: 1 strong support context, 2 support contexts.
   - `JAK1`, `IL7R`, `CD80`: each 1 strong support context.
   - `NCF1`: 3 support contexts, no strong context.
   - `SRC`, `SYK`, `CD274`, `JAK2`: weaker support; all blocked.

## Interpretation

The branch converges biologically but not therapeutically. The recurring
pattern is an Fc receptor/ROS myeloid-handling state coupled to checkpoint,
costimulation, and cytokine/JAK response. The obvious ways to intervene
(`FCGR2A/B`, `NCF1/NOX2`, `SYK/SRC/LYN`, `JAK`, `PD-1/PD-L1`, `CD80/CD28`,
`TL1A`) are blocked by prior art, directionality, host-defense risk, or broad
immune suppression.

The attempted less-blocked controller escape route (`PRKDC`, `BLK`) failed the
foundation-model check.

## Decision

Do not promote any Wave69 direct target or controller. Continue the session by
pivoting from direct target nomination to either:

1. a modality-specific Fc/ROS resolution strategy with a real selectivity
   mechanism, or
2. a different cross-autoimmune axis outside the current blocked
   checkpoint/Fc/JAK/costimulation neighborhood.
